



TOTAL NUMBER OF VOTING RIGHTS AND SHARES

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority).

Date	Total number of shares	Number of existing voting rights (GROSS)	Number of existing voting rights (NET)
01/31/2018	71, 204, 928*	72, 875, 696	72, 354, 288

** including 9 597 565 new shares from the conversion of bonds issuing in November 22, 2017 and the exercise of BSAR issued for all the shareholders in November 24, 2017.*

About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by 4 patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology, allergies and Type 1 diabetes. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

For more information on Neovacs, visit www.neovacs.fr

NEOVACS – Investor Relations

Charlène Masson
+33 (0)1 53 10 93 00
cmasson@neovacs.com

Investor Relations / Financial Communications – Life Science Advisors

Chris Maggos
chris@lifesciadvisors.com